FDA grants fast-track status to Rebiotix's stool transplant

06/25/2013 | Minneapolis/St. Paul Business Journal

Rebiotix has received fast-track designation from the FDA for its fecal transplant, which could speed up marketing approval for the product. The Roseville, Minn.-based biotech startup intends to use the product for patients with Clostridium difficile, a type of hospital-acquired bacterial infection.

View Full Article in:

Minneapolis/St. Paul Business Journal

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park